• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
NMS-1286937

NMS-1286937

Product ID N5072
Cas No. 1034616-18-6
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $142.80 In stock
5 mg $228.10 In stock
10 mg $346.10 Please Inquire
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

NMS-1286937 is an inhibitor of polo-like kinase 1 (PLK1) that is currently in clinical trials as a potential treatment for various cancers; it exhibits anticancer chemotherapeutic activity. In osteosarcoma cells, NMS-1286937 induces cell cycle arrest and apoptosis and inhibits cell growth. In animal models of acute myelogenous leukemia (AML), this compound increases survival time and decreases tumor cell infiltration. Additionally, NMS-1286937 inhibits cell proliferation and induces apoptosis, cell cycle arrest, and tumor regression in cellular and animal models of colon cancer.

Product Info

Cas No.

1034616-18-6

Purity

≥98%

Formula

C24H27F3N8O3

Formula Wt.

532.52

IUPAC Name

1-(2-Hydroxyethyl)-8-{[5-(4-methyl-1-piperazinyl)-2-(trifluoromethoxy)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide

Synonym

NMS1286937, NMS-P937

Solubility

DMSO 42 mg/mL warmed (78.87 mM) Ethanol 10 mg/mL warmed (18.77 mM) Water Insoluble

Appearance

White to off white powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

N5072 MSDS PDF

Info Sheet

N5072 Info Sheet PDF

References

Sero V, Tavanti E, Vella S, et al. Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance. Invest New Drugs. 2014 Dec;32(6):1167-80. PMID: 25193492.

Casolaro A, Golay J, Albanese C, et al. The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. PLoS One. 2013;8(3):e58424. PMID: 23520509.

Valsasina B, Beria I, Alli C, et al. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther. 2012 Apr;11(4):1006-16. PMID: 22319201.

Beria I, Bossi RT, Brasca MG, et al. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett. 2011 May 15;21(10):2969-74. PMID: 21470862.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • G8850

    GW-5074

    c-Raf inhibitor.

    ≥98%
  • O7053

    L-Ornithine Hydrochloride

    Non-proteinogenic amino acid, L-arginine metabo...

    ≥98%
  • G880000

    GW 405833

    Cannabinoid receptor 2 selective agonist.

    ≥98%
  • E6996

    Erythromycin Thiocyanate

    Macrolide; protein translation inhibitor, mamma...

    ≥90%
  • M177521

    Menaquinone-7

    2-methyl-1,4-naphthoquinone derivative

    98%
  • O9322

    Oxfendazole

    Benzimidazole; microtubule polymerization inhib...

    ≥98%
  • C0171

    Carboplatin

    Pt-based DNA cross-linker.

    ≥99%
  • F3354

    Finasteride

    Steroid 5-α-reductase inhibitor.

    ≥98%
  • I6933

    Irinotecan Hydrochloride Trihydrate

    Camptothecin analog; topoisomerase I inhibitor,...

    ≥98%
  • J023736

    (±)-Jasmonic Acid

    Phytohormone

    ≥98% (sum of isomers)
  • A1369

    Adrenomedullin (13-52), human

    Endogenous peptide hormone, involved in cell gr...

    ≥95%
  • S8253

    Sunitinib Malate

    Indoline; PDGFR, VEGFR, c-KIT, FLT3, mTORC1 inh...

    ≥98%
  • R1878

    Retinyl Acetate

    Vitamin A derivative, acetate ester of retinol....

    ≥98%
  • L0211

    Lactulose

    Synthetic non-digestible disaccharide.

    ≥99%
  • A046189

    Abexinostat

    Primarily targets HDAC1

    ≥98%
  • O1200

    Odanacatib

    Cathepsin K inhibitor.

    ≥99%
  • T5060

    TMP-269

    HDAC inhibitor.

    ≥98%
  • P0370

    Paromomycin Sulfate

    Aminoglycoside; protein translation inhibitor, ...

    ≥98%
  • R5878

    Rotenone

    Micronuclei formation inducer, antimitotic, oxi...

    ≥97%
  • T5769

    Toremifene Base

    SERM, androgen modulator.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only